BTA9881

DB05226InvestigationalSmall molecule

BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

Mechanism: BTA9881 is a small molecule fusion glycoprotein inhibitor, designed to specifically inhibit the process by which respiratory syncytial virus (RSV) infects a cell.
Curator reviewed
Primary indication: For the treatment of respiratory syncytial virus infections.Curator reviewed
Code names: BTA 9881 · MEDI-564

Resolves to

Compound

Targets

What you can answer from here — as of June 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

Which drugs share a target with BTA9881, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.